<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44010">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533375</url>
  </required_header>
  <id_info>
    <org_study_id>M14-193</org_study_id>
    <nct_id>NCT02533375</nct_id>
  </id_info>
  <brief_title>Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)</brief_title>
  <official_title>A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate efficacy, safety and pharmacokinetics of adalimumab
      in Japanese subjects with generalized pustular psoriasis (GPP).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving clinical response</measure>
    <time_frame>From Week 0 to Week 16</time_frame>
    <description>Clinical Response is defined as reduction of skin score relative to the baseline (week 0), according to Japan Dermatology Association (JDA) severity index in Generalized Pustular Psoriasis (GPP) medical care guideline 2014 in Japan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total GPP score</measure>
    <time_frame>From Week 2 to Week 52</time_frame>
    <description>Total GPP score is sum of total skin score and total systemic and laboratory test score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total skin score</measure>
    <time_frame>From Week 2 to Week 52</time_frame>
    <description>Total skin score is sum of scores of erythema (total), erythema with pustule and edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Surface Area of each component of skin score</measure>
    <time_frame>From Week 2 to Week 52</time_frame>
    <description>Components of skin score are erythema (total), erythema with pustule and edema</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of adverse events (AEs)</measure>
    <time_frame>Up to 10 weeks after the last dose of the study medication</time_frame>
    <description>Treatment emergent AEs are defined as events that begin or worsen either on or after the first dose day of the study medication and within 70 days (10 weeks) after the last dose of the study medication.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Generalized Pustular Psoriasis (GPP)</condition>
  <condition>Adalimumab</condition>
  <condition>Japanese</condition>
  <arm_group>
    <arm_group_label>Patients receiving adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection at Week 0 and then every other week on and after Week 2. Dose escalation is allowed for subjects who do not have appropriate response on or after Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab</description>
    <arm_group_label>Patients receiving adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of generalized pustular psoriasis

          -  Total skin score of at least 3 and erythema with pustule at the Baseline in Japan
             Dermatology Association (JDA) severity index of Generalized Pustular Psoriasis (GPP)
             in GPP Medical Care Guideline 2014 in Japan

          -  Inadequate response to, or intolerance to, or contraindication to the approved GPP
             treatment (excluding infliximab)

          -  Infliximab secondary failure, or intolerant to infliximab

        Exclusion Criteria:

          -  Erythrodermic psoriasis, guttate psoriasis or sub-corneal pustular dermatosis

          -  Drug-induced GPP

          -  Cannot stop ongoing use of prohibited GPP treatments

          -  Total JDA severity index of GPP of 14 or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138572</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138568</name>
      <address>
        <city>Morioka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138584</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140565</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138573</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138591</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139344</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139345</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139346</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141689</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
    <description>AbbVie</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>August 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
